Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
The unambiguous benefit of thrombectomy in patients with emergent large vessel occlusion (ELVO) has now been demonstrated in five multicenter, prospective, randomized controlled trials.1–5 These trials ended just months after three randomized controlled trials had shown no benefit for thrombectomy.6–8
The positive trials differ from the negative trials in three important ways. First, modern thrombectomy devices (primarily stent retrievers) were used in each of the positive trials. Patients in the negative trials were primarily treated with intra-arterial thrombolytic infusions and the MERCI device, which have been shown to be much less effective in achieving an effective revascularization. Second, the positive trials mandated vascular imaging to confirm large vessel occlusion before enrollment. Confirmation of large vessel occlusion was a requirement for only the smallest of the earlier negative trials. A subsequent subgroup analysis of the largest trial indicated that for those patients with confirmation of large vessel occlusion there appeared to be a benefit for thrombectomy. Third, with experience derived from prior studies, the exclusion of patients with large areas of completed infarct and little likelihood of improving after endovascular therapy was recognized to be of critical importance. In three of the five positive trials, advanced imaging applications were incorporated into the screening process to help investigators exclude patients with large areas of completed infarction, and the others used either a ‘grey principle’ or the ASPECTS score to allow proceduralists to screen patients before enrollment. There were other differences in the design of the positive trials, but these three major differences, largely consistent across trials, accounted for their overwhelming and uniform positivity.
These data have resulted …
Correction notice This article has been corrected since it published Online First. The competing interest statement has been amended and the author Sean Lavine's name corrected.
Competing interests JM: consultant – Lazurus Effect, Reverse, Pulsar, Edge Therapeutics, Medina; investor – Blockade Medical, Medina, Lazurus Effect. ASA: research support – Sequent and Siemens; consultant – Microvention, Johnson and Johnson, Medtronic, Penumbra, Silk Road, Stryker, Sequent; stock – Lazarus Effect and Valor. DF: consultant – Medtronic/Covidien, Stryker, Penumbra, Codman, Siemens. RDT: consultant – Penumbra, Covidien/Medtronic, Codman, Blockade, Pulsar vascular, Microvention. AT: consultant and research grant – Stryker, Penumbra, Microvention; research grant – Medtronic; consultant and shareholder – Medina Medical, Lazarus Effect, Pulsar Vascular. AHS: consultant – Codman & Shurtleff Inc, Covidien Vascular Therapies, GuidePoint Global Consulting, Penumbra, Stryker, Pulsar Vascular, Microvention, Lazarus Effect, Blockade Medical, Reverse Medical, WL Gore & Associates, Medina Medical, Cervetech Inc, Neuroavi, Perflow Medical, Silkroad Medical, TRES Medical, Syntervention; research grants – The National Institutes of Health; financial interests – Hotspur, Intratech Medical, StimSox, Valor Medical, Blockade Medical, Lazarus Effect, Pulsar Vascular, Medina Medical Inc; national steering committees – Penumbra, 3D Separator Trial, Covidien, SWIFT PRIME Trial, LARGE Trial, POSITIVE Trial, Codman, BRAVO Trial, Neuroavi, ARISE II Trial; advisory board – Codman & Shurtleff, Covidien Neurovascular, Inter-societal Accreditation Commission. WJM: consultant – Medtronic (DSMB), Penumbra (DSMB), Lazarus Effect. AA: speaker bureau – Genentech. JAH: consultant – medtronic; shareholder – Intratech.
Provenance and peer review Commissioned; internally peer reviewed.